Crixivan

RSS

indinavir

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Crixivan has been withdrawn at the request of the marketing-authorisation holder.

This EPAR was last updated on 12/07/2022

Authorisation details

Product details
Name
Crixivan
Agency product number
EMEA/H/C/000128
Active substance
indinavir sulfate ethanolate
International non-proprietary name (INN) or common name
indinavir
Therapeutic area (MeSH)
HIV Infections
Anatomical therapeutic chemical (ATC) code
J05AE02
Publication details
Marketing-authorisation holder
Merck Sharp & Dohme B.V.
Revision
39
Date of issue of marketing authorisation valid throughout the European Union
04/10/1996
Contact address

Waarderweg 39
2031 BN Haarlem
The Netherlands

Product information

03/08/2018 Crixivan - EMEA/H/C/000128 - T/0104

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antivirals for systemic use

Therapeutic indication

Crixivan is indicated in combination with antiretroviral nucleoside analogues for the treatment of HIV-1 infected adults.

Assessment history

How useful was this page?

Add your rating